Dr. Frank Torti is a prominent leader in the biopharmaceutical sector, serving as Vant Chair at Roivant Sciences and Executive Chairman at Immunovant. His career is highlighted by founding Telavant and leading it to a $7. 25B acquisition by Roche. He holds a unique combination of an MD from UNC and an MBA from Harvard.
He has a deep personal connection to medicine, as his father is a lifelong cancer doctor and a former Acting Commissioner at the United States Food and Drug Administration. Dr. Torti actively promotes his fathers work, underscoring a commitment to patient advocacy that extends beyond his corporate roles.
He has overseen companies that have advanced over forty medicines into clinical development and achieved positive phase three results in ten consecutive trials.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.